4.6 Letter

Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats

期刊

MOVEMENT DISORDERS
卷 23, 期 12, 页码 1794-1795

出版社

WILEY
DOI: 10.1002/mds.21820

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Restoration of c-Src/Fyn Proteins Rescues Mitochondrial Dysfunction in Huntington's Disease

Ligia Fao, Patricia Coelho, Luis Duarte, Rita Vilaca, Michael R. Hayden, Sandra I. Mota, Ana Cristina Rego

Summary: This study demonstrates that c-Src/Fyn proteins play an important role in controlling mitochondrial function and redox regulation in Huntington's disease (HD). Restoring c-Src/Fyn levels in HD improves mitochondrial morphology and function, reducing the levels of oxidant species and cell death. These findings suggest that c-Src/Fyn could be a potential therapeutic target for HD.

ANTIOXIDANTS & REDOX SIGNALING (2023)

Article Cell Biology

Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine

Shao-Ming Wang, Hsiang-En Wu, Yuko Yasui, Michal Geva, Michael Hayden, Tangui Maurice, Mauro Cozzolino, Tsung-Ping Su

Summary: Autophagy is a crucial cellular process with implications in various diseases. In this study, researchers discovered that the molecular chaperone SIGMAR1 is involved in the transport of TFEB into the nucleus by chaperoning the NP protein POM121, which is responsible for recruiting KPNB1. The disruption of this process in ALS-FTD patients with the C9orf72 subtype leads to impaired autophagy. However, overexpression of SIGMAR1 or POM121, as well as treatment with pridopidine, a SIGMAR1 agonist, can rescue these deficits, suggesting their potential therapeutic use.

AUTOPHAGY (2023)

Article Biochemistry & Molecular Biology

Mitochondrial and redox modifications in early stages of Huntington's disease

Carla Lopes, I. Luisa Ferreira, Carina Maranga, Margarida Beatriz, Sandra I. Mota, Jose Sereno, Joao Castelhano, Antero Abrunhosa, Francisco Oliveira, Maura De Rosa, Michael Hayden, Mario N. Laco, Cristina Januario, Miguel Castelo Branco, A. Cristina Rego

Summary: Deficits in mitochondrial function and redox deregulation occur in early stages of Huntington's disease and can progress with disease manifestation.

REDOX BIOLOGY (2022)

Article Astronomy & Astrophysics

The GALAH survey: chemical clocks

Michael R. Hayden, Sanjib Sharma, Joss Bland-Hawthorn, Lorenzo Spina, Sven Buder, Ioana Ciuca, Martin Asplund, Andrew R. Casey, Gayandhi M. De Silva, Valentina D'Orazi, Ken C. Freeman, Janez Kos, Geraint F. Lewis, Jane Lin, Karin Lind, Sarah L. Martell, Katharine J. Schlesinger, Jeffrey D. Simpson, Daniel B. Zucker, Tomaz Zwitter, Boquan Chen, Klemen Cotar, Diane Feuillet, Jonti Horner, Meridith Joyce, Thomas Nordlander, Dennis Stello, Thor Tepper-Garcia, Yuan-sen Ting, Purmortal Wang, Rob Wittenmyer, Rosemary Wyse

Summary: This study presents the first large-scale study on determining the ages of a large sample of stars through Galactic chemical evolution. Using the machine learning algorithm XGBoost, the ages of 214,577 stars in GALAH DR3 were estimated, yielding precise results to 1-2 Gyr.

MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY (2022)

Article Neurosciences

Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model

Sophie Lenoir, Romane A. Lahaye, Helene Vitet, Chiara Scaramuzzino, Amandine Virlogeux, Laetitia Capellano, Aurelie Genpux, Noga Gershoni-Emek, Michal Geva, Michael R. Hayden, Frederic Saudou

Summary: Huntington's disease is a neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. Pridopidine, a sigma-1 receptor agonist, enhances the availability of BDNF to protect neurons in HD.

NEUROBIOLOGY OF DISEASE (2022)

Article Biology

Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models

Pawel Joachimiak, Adam Ciesiolka, Emilia Kozlowska, Pawel M. Switonski, Grzegorz Figura, Agata Ciolak, Grazyna Adamek, Magdalena Surdyka, Zaneta Kalinowska-Poska, Maciej Figiel, Nicholas S. S. Caron, Michael R. R. Hayden, Agnieszka Fiszer

Summary: This study used SNP variants to quantitatively determine the allele-specific expression levels in patient-derived cell lines for spinocerebellar ataxia type 3 (SCA3) and Huntington's disease (HD). They found differences in allele expression levels and developed a reliable and quantitative method using SNP-based droplet digital PCR (ddPCR) to analyze low abundant transcripts. This allele-selective approach provides insights into allele-related mechanisms and can improve understanding of polyglutamine diseases.

BMC BIOLOGY (2023)

Article Physiology

Full-length huntingtin is palmitoylated at multiple sites and post-translationally myristoylated following caspase-cleavage

Fanny L. Lemarie, Shaun S. Sanders, Yen Nguyen, Dale D. O. Martin, Michael R. Hayden

Summary: Huntington's disease is a neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. We found that huntingtin protein can be palmitoylated at cysteine 214, and proteolytic cleavage at aspartate 552 leads to myristoylation at glycine 553. Blocking caspase cleavage at aspartate 586 increases myristoylation of huntingtin and promotes the interaction between C-terminal and N-terminal fragments.

FRONTIERS IN PHYSIOLOGY (2023)

Article Neurosciences

Huntingtin Overexpression Does Not Alter Overall Survival in Murine Cancer Models

Laura Lynn Chan, Austin Hill, Ge Lu, Jeremy Van Raamsdonk, Randy Gascoyne, Michael R. Hayden, Blair R. Leavitt

Summary: There is no significant effect of mutant or overexpression of huntingtin protein on overall survival in mouse models of cancer, which contradicts the hypothesis that mutant huntingtin expression is protective against cancer.

JOURNAL OF HUNTINGTONS DISEASE (2022)

Article Neurosciences

Axonal ER Ca2+ Release Selectively Enhances Activity-Independent Glutamate Release in a Huntington Disease Model

James P. Mackay, Amy I. Smith-Dijak, Ellen T. Koch, Peng Zhang, Evan Fung, Wissam B. Nassrallah, Caodu Buren, Mandi Schmidt, Michael R. Hayden, Lynn A. Raymond

Summary: Miniature neurotransmission is increased in the Huntington disease (HD) model, associated with abnormal endoplasmic reticulum (ER) calcium handling. These abnormalities influence neurotransmission indirectly, without direct ER calcium release into the cytoplasm. However, in cortical cultures and brain slices, there are no significant differences in calcium release between the HD-model neurons and wild-type cells.

JOURNAL OF NEUROSCIENCE (2023)

Article Behavioral Sciences

Progressive alterations in white matter microstructure across the timecourse of Huntington's disease

Carlos Estevez-Fraga, Michael S. Elmalem, Marina Papoutsi, Alexandra Durr, Elin M. Rees, Nicola Z. Hobbs, Raymund A. C. Roos, Bernhard Landwehrmeyer, Blair R. Leavitt, Douglas R. Langbehn, Rachael I. Scahill, Geraint Rees, Sarah J. Tabrizi, Sarah Gregory

Summary: This study investigated the longitudinal changes in white matter microstructure in Huntington's disease and found significant alterations in larger white matter areas as the disease progressed, indicating a progressive deterioration of white matter microstructure with disease evolution.

BRAIN AND BEHAVIOR (2023)

Article Clinical Neurology

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose

Borje Darpo, Michal Geva, Georg Ferber, Yigal Paul Goldberg, Andres Cruz-Herranz, Munish Mehra, Richard Kovacs, Michael R. Hayden

Summary: Pridopidine, a selective sigma-1 receptor agonist, shows a favorable cardiac safety profile at the therapeutic dose of 45 mg bid, with no clinically relevant effect on the QT interval.

NEUROLOGY AND THERAPY (2023)

Article Biotechnology & Applied Microbiology

Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency

Neel Mehta, Renald Gilbert, Parminder S. Chahal, Maria J. Moreno, Nasha Nassoury, Nathalie Coulombe, Viktoria Lytvyn, Mario Mercier, Dorothy Fatehi, Wendy Lin, Emily M. Harvey, Lin-Hua Zhang, Nazila Nazemi-Moghaddam, Seyyed Mehdy Elahi, Colin J. D. Ross, Danica B. Stanimirovic, Michael R. Hayden

Summary: This study aimed to develop a more efficacious AAV gene therapy vector for the treatment of LPLD. The researchers identified AAV8 pVR59 as a superior vector compared to AAV1 (Glybera), with significantly better therapeutic effects at lower doses. AAV8 pVR59 treatment led to long-term correction of LPLD and improvement in pathology.

HUMAN GENE THERAPY (2023)

Article Biotechnology & Applied Microbiology

Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders

Fabio Duarte, Gabriel Vachey, Nicholas S. Caron, Melanie Sipion, Maria Rey, Anselme L. Perrier, Michael R. Hayden, Nicole Deglon

Summary: Huntington's disease is a fatal neurodegenerative disorder that can be treated by inactivating the mutated HTT gene. One approach to selectively inactivate the mutant allele is by using the CRISPR/Cas9 system to remove the first exon of the mutated HTT. However, the frequency of deletion events is still uncertain.

HUMAN GENE THERAPY (2023)

Meeting Abstract Oncology

Stereotactic Radiosurgery for Trigeminal Neuralgia Secondary to Tumor: A Single Institutional Retrospective Series

J. C. Hall, T. H. Ung, T. L. McCleary, C. F. Chuang, I. C. Gibbs, S. G. Soltys, M. Hayden, G. Li, E. Pollom, S. D. Chang, A. Meola

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Meeting Abstract Clinical Neurology

CEREBROSPINAL FLUID BIOMARKERS FOR ASSESSING HUNTINGTON DISEASE ONSET AND SEVERITY

Nicholas S. Caron, Arsalan S. Haqqani, Akshdeep Sandhu, Amirah E. Aly, Hailey Findlay Black, Jeffrey N. Bone, Jodi L. McBride, Abedelnasser Abulrob, Danica Stanimirovic, Blair R. Leavitt, Michael R. Hayden

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

暂无数据